Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728454 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01728454 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT01728454, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the safety and efficacy of two oral doses of telapristone acetate administered to premenopausal women with pelvic pain associated with endometriosis confirmed within the last seven years and using prescription analgesics for symptomatic pain.
Interventions
- DRUG Placebo
- DRUG Telapristone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-05-02 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728454
The ClinicalTrials.gov registry entry for NCT01728454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01728454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728454 about?
NCT01728454 is a clinical study titled "Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis". The primary purpose of this study is to determine the safety and efficacy of two oral doses of telapristone acetate administered to premenopausal women with pelvic pain associated with endometriosis confirmed within the last seven years and using prescription analgesics for symptomatic pain.
What is the current status of trial NCT01728454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2013-05-02. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT01728454?
The interventions under investigation include: Placebo (DRUG), Telapristone acetate (DRUG).
Who is sponsoring clinical trial NCT01728454?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.